Jacob Drobnyk Soumerai

机构：Massachusetts General Hospital, Global Cancer Institute, Center for Cancer Research · ORCID：0000-0002-3062-6819

发表论文 189 篇 · 总被引 4783 次 · h-index 27

代表论文

• Clinical presentation, management, and outcome of TIAN in CNS lymphoma treated with CD19-CAR T-cell therapy (2025 · Blood · 被引 18)
• Preliminary safety and efficacy of boven (Zanubrutinib, Obinutuzumab, and Venetoclax) as frontline therapy for older patients with Mantle Cell Lymphoma (2025 · Blood · 被引 5)
• Post-treatment outcomes of TP53-mutant Mantle Cell Lymphoma patients treated with frontline zanubrutinib, obinutuzumab, and venetoclax (BOVen): Durable responses in patients who achieve complete remissions with undetectable MRD (2025 · Blood · 被引 4)
• Patterns, risk factors and management of CD19-directed chimeric antigen receptor T-cell therapy failure in CNS lymphoma (2026 · Journal of Hematology & Oncology · 被引 3)
• 49 | COMBINATION TREATMENT WITH NOVEL BCL2 INHIBITOR SONROTOCLAX (BGB‐11417) + ZANUBRUTINIB INDUCES HIGH RATE OF COMPLETE REMISSION IN RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA (2025 · Hematological Oncology · 被引 2)
• Frontline treatment of sonrotoclax (BGB-11417) and zanubrutinib for chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) demonstrates high undetectable minimal residual disease (uMRD) rates with favorable tolerability: Updated data from BGB-11417-101, an ongoing phase 1/1b study (2025 · Blood · 被引 1)